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OBJECTIVES Evaluate the safety, tolerability and preliminary efficacy of intracoronary (IC) basic fibroblast
growth factor (bFGF, FGF-2).
BACKGROUND FGF-2 is a heparin-binding growth factor capable of inducing functionally significant
angiogenesis in animal models of myocardial ischemia.
METHODS Phase I, open-label dose-escalation study of FGF-2 administered as a single 20-min infusion
in patients with ischemic heart disease not amenable to treatment with CABG or PTCA.
RESULTS Fifty-two patients enrolled in this study received IC FGF-2 (0.33 to 48 mg/kg). Hypotension
was dose-dependent and dose-limiting, with 36 mg/kg being the maximally tolerated dose.
Four patients died and four patients had non-Q-wave myocardial infarctions. Laboratory
parameters and retinal examinations showed mild and mainly transient changes during the
6-month follow-up. There was an improvement in quality of life as assessed by Seattle Angina
Questionnaire and improvement in exercise tolerance as assessed by treadmill exercise testing
(510 6 24 s at baseline, 561 6 26 s at day 29 [p 5 0.023], 609 6 26 s at day 57 (p , 0.001),
and 633 6 24 s at day 180 (p , 0.001), overall p , 0.001). Magnetic resonance (MR)
imaging showed increased regional wall thickening (baseline: 34 6 1.7%, day 29: 38.7 6 1.9%
[p 5 0.006], day 57: 41.4 6 1.9% [p , 0.001], and day 180: 42.0 6 2.3% [p , 0.001], overall
p 5 0.001) and a reduction in the extent of the ischemic area at all time points compared with
baseline.
CONCLUSIONS Intracoronary administration of rFGF-2 appears safe and is well tolerated over a 100-fold
dose range (0.33 to 0.36 mk/kg). Preliminary evidence of efficacy is tempered by the
open-label uncontrolled design of the study. (J Am Coll Cardiol 2000;36:2132–9) © 2000 by
the American College of Cardiology
Despite recent advances in the treatment of coronary artery
disease (CAD), a significant number of patients cannot be
adequately managed by either medical therapy or by cur-
rently available revascularization procedures including per-
cutaneous transluminal angioplasty (PTCA) and coronary
artery bypass surgery (CABG) (1,2). An alternative treat-
ment strategy is therefore warranted in these patients both
to control symptoms and improve quality of life, as well as
to alter the natural course of advanced ischemic heart
disease. Therapeutic angiogenesis may serve that role by
promoting development of collateral blood vessels (3–5).
Angiogenesis is a complex process that involves endothe-
lial cell migration and proliferation, extracellular matrix
breakdown, attraction of pericytes and macrophages,
smooth muscle cell proliferation and migration, formation
and “sealing” of new vascular structures, and deposition of
new matrix (6–8). A number of growth factors, including
the fibroblast growth factors (FGF) and vascular endothelial
growth factors (VEGF) are integrally involved in the an-
giogenic response in ischemic conditions and in certain
pathological states (6). The availability of these factors has
led to studies, which have demonstrated a therapeutic
benefit in various animal models of acute and chronic
myocardial ischemia (4,5,9). In particular, basic fibroblast
growth factor (bFGF, FGF-2) is an attractive candidate as
an agent for therapeutic angiogenesis.
FGF-2, a 16.5 kD 146 amino acid heparin-binding
protein, is a pluripotent mitogen capable of stimulating
migration and proliferation of a variety of cell types includ-
ing fibroblasts, macrophages, smooth muscle and endothe-
lial cells (10). In addition to these mitogenic properties,
FGF-2 can stimulate endothelial production of various
proteases, including plasminogen activator and matrix met-
alloproteinases, induce significant vasodilation through
stimulation of nitric oxide release (11,12) and promote
chemotaxis. FGF-2 is present in the normal myocardium
(13) and its expression is potentiated by hypoxia (14,15) or
hemodynamic stress (16). Because of its heparin-binding
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properties, FGF-2 binds avidly (Kd 1029 M) to endothelial
cell surface heparan sulfates (17). This interaction serves to
prolong effective tissue half-life of the FGF-2 protein (18),
facilitates its binding to its high-affinity receptors (19) and
plays a key role in stimulation of cell proliferation and
migration (20,21).
A number of studies have demonstrated the ability of
FGF-2 to induce functionally significant angiogenesis in
several different animal models of myocardial ischemia.
Intracoronary (IC) injections of FGF-2 in the setting of
acute coronary thrombosis in dogs or pigs lead to signifi-
cantly higher vessel counts and reduction in infarct size in
growth factor-treated animals compared with controls (22–
24). Continuous administration of FGF-2 in the setting of
chronic ischemia, either directly into the occluded coronary
artery or into the left atrium, resulted in augmentation of
coronary flow in the growth factor-treated animals (25,26).
Sustained release perivascular administration or intraperi-
cardial delivery of FGF-2 not only improved myocardial
blood flow in the ischemic myocardium but also improved
regional left ventricular function in the ischemic zone
(9,27,28).
Single bolus IC administration of FGF-2 has obvious
practical advantages compared with administration of
sustained-release preparations or multiple repetitive injec-
tions. We therefore conducted a Phase I, open-label dose-
escalation study of intracoronary FGF-2 in patients with
severe ischemic heart disease in order to determine the
maximally tolerated dose (MTD) and to evaluate feasibility,
safety and preliminary efficacy of this mode of therapy.
Herein, we report the acute results and six months
follow-up data.
METHODS
Patient selection. The study was conducted at two centers,
the Beth Israel Deaconess Medical Center (Boston, Mas-
sachusetts) and Emory University Hospital (Atlanta, Geor-
gia), and patients were enrolled between December 1997
and July 1998. The study was approved by the Institutional
Review Boards at both hospitals. The inclusion criteria
selected for patients with advanced CAD with inducible
ischemia and who were considered to be suboptimal
candidates for either PTCA or CABG. Patients were
excluded from the study if they had any of the following
criteria: uncompensated congestive heart failure or an ejec-
tion fraction ,20%; a myocardial infarction within three
months; new onset of angina or unstable angina within
three weeks; PTCA, CABG, stroke or transient ischemic
attack within six months; uncontrolled hemodynamically
significant arrhythmias; critical valvular disease; restrictive
or hypertrophic cardiomyopathy; arteriovenous malforma-
tions; proliferative retinopathy, retinal vein occlusion, or
macular edema; renal insufficiency (creatinine clearance ,
80 ml/min by 24-h urine collection); vasculitis or chronic
immunosuppressive therapy; or any malignancy within the
past 10 years (except for curatively treated nonmelanoma
skin cancer). Patients with diabetes mellitus were eligible if
they had no proliferative retinopathy or severe nonprolif-
erative retinopathy, and no microalbuminuria.
Study design. This was an open-label interpatient dose
escalation study. The initial dose of 0.33 mg/kg was esca-
lated over eight sequential groups to 48 mg/kg IC. At least
four patients were studied at each dose. If no patient
experienced dose-limiting toxicity as defined by the protocol
within six days, the dose was escalated; if one patient
experienced dose-limiting toxicity, an additional four pa-
tients were studied at that dose. The MTD was defined as
the dose tolerated by 9 of 10 patients.
Study procedures. After providing informed consent and
meeting all eligibility criteria, patients underwent baseline
evaluations that included a complete medical history and
physical examination, an ophthalmologic examination with
fundus photography read by a core laboratory using the
Early Treatment Diabetic Retinopathy score (ETDRS), an
exercise tolerance test (ETT), a Seattle Angina Question-
naire (SAQ) (29,30), and nuclear and MRI cardiac scans.
Measurement of initial health status allowed the use of
change in scores, thus adjusting for differences in baseline
health. Self-administration was used instead of telephone
interview to minimize data collection bias (29,30).
On day 1, patients underwent right and left heart
catheterization and coronary angiography. If the coronary
anatomy was not amenable to PTCA or CABG, recombi-
nant FGF-2 (rFGF-2, Chiron Corporation, Emeryville,
CA) was infused with a Baxter pump through diagnostic
catheters into two major conduits of myocardial blood
supply over 20 min (10 min in each vessel) with continuous
monitoring of systemic blood pressure and right atrial and
pulmonary capillary wedge pressures, and cardiac output. In
occasional patients the entire dose was infused into a single
vessel that was believed to be the major source of blood
supply. Prior to initiation of rFGF-2 infusion, normal saline
was administered intravenously (IV), if required, to ensure
mean pulmonary capillary wedge pressure .12 mm Hg.
Heparin (40 U/kg) was administered IV more than 10 min
before rFGF-2. The volume of infusion varied with dose
and the patient’s weight, ranging from 10 ml at lower doses
to 40 ml at higher doses.
Abbreviations and Acronyms
CAD 5 coronary artery disease
CABG 5 coronary artery bypass surgery
ETDRS 5 early treatment diabetic retinopathy
ETT 5 exercise tolerance test
FGF 5 fibroblast growth factor
IC 5 intracoronary
MRI 5 magnetic resonance imaging
MTD 5 maximally tolerated dose
PTCA 5 percutaneous transluminal angioplasty
SAQ 5 Seattle Angina Questionnaire
VEGF 5 vascular endothelial growth factor
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The right heart (Swan–Ganz) catheter was left in place
for 7 h following drug infusion to monitor filling pressures
and cardiac output. Patients were monitored with full-
disclosure telemetry for 24 h following rFGF-2 administra-
tion. Patients were discharged 24 h after study drug infusion
and clinical follow-up visits were performed at days 6, 15,
29, 57, 180 and 360. Quality of life was assessed using the
Seattle Angina Questionnaire at baseline and days 57 and
180. ETTs were obtained at days 29, 57 and 180. Exercise
stressed nuclear perfusion scans (rest thallium/stress 99mTc-
sestamibi) and resting cardiac magnetic resonance scans
were performed at days 29, 57 and 180.
Safety assessment. The safety of intracoronary rFGF-2
was assessed through clinical observations, electrocardiog-
raphy, hemodynamic monitoring, hematologic and serum
chemistry profiles, development of anti-rFGF-2 antibodies,
detailed ophthalmological exams with fundus photography
and assessment of renal function by determination of
creatinine clearance and proteinuria using 24-h urine col-
lection.
Dose-limiting toxicity was predefined as persistent
(.10 min) drop in systolic blood pressure by .50 mm Hg,
change in heart rate to .120/min or to ,50/min, new
clinically significant arrhythmia, new ischemic symptoms or
ECG changes, new congestive heart failure, deterioration in
renal function or any other serious adverse events.
Magnetic resonance (MR) imaging. Magnetic resonance
(MR) imaging was performed at baseline and days 29, 57
and 180 in the body coil of a 1.5 T whole-body Siemens
Vision or Phillips NT system. Functional imaging was
performed during breath-hold using shared-center FLASH
or multishot echoplanar imaging in each of the three
mutually perpendicular standard views, producing 16–24
sequential image frames each, collected over approximately
12 heartbeats to measure regional wall systolic thickening.
MR blood arrival imaging was assessed as previously de-
scribed (31). A series of four inversion recovery images was
obtained with the inversion time (TI) adjusted to minimize
signal intensity from myocardium. Using the best TI for
nulling myocardial signal, a series of concurrent parallel
images were acquired in diastole during breathhold, at
baseline and after the bolus injection of contrast media (0.05
mmol/kg gadodiamide) (31,32). Measurement of the timing
of half-maximum signal arriving in the different parts of the
myocardium demonstrated the existence of several distinct
regions, including normal myocardium and areas exhibiting
delayed contrast arrival (ischemic zones). For each scan, a
space-time map demonstrating distribution of contrast sig-
nal density over the left ventricular wall as a function of time
was created. The extent of the territory demonstrating
delayed arrival of contrast, defined as .1-s delay of contrast
density reaching its 50% maximum value reflecting the most
severely hypoperfused part of the myocardium, was then
calculated and expressed as percent of the total left ventric-
ular myocardial area (31). MR analysis was performed by a
core lab blinded to rFGF-2 dose assignment and to study
sequence.
Statistical methods. Data are pooled for all dose groups.
Baseline characteristics and acute hemodynamic parameters
are expressed as mean 6 standard deviation. Efficacy vari-
ables were analyzed using a linear mixed effects model with
an unstructured covariance assumption for the repeated
measurements, fit using the restricted maximum likelihood
method. Model-based estimates of the means 6 standard
errors (SEM) are presented. An overall F-test for equality
across all time points was conducted first. If this initial test
was statistically significant, pairwise t tests to compare
baseline with each on-study time point were performed at
the nominal a-level. All reported p-values are two-sided,
and a p-value , 0.05 was considered statistically significant.
RESULTS
Patient population. Fifty-two patients met all eligibility
criteria and received a single IC infusion of rFGF-2. Their
baseline characteristics are summarized in Table 1. The
mean age was 60.8 6 10.1 years (range 41 to 80) and 2 of
52 patients were women. Six patients (11%) had diabetes
mellitus and 31 patients (60%) had elevated cholesterol
(serum cholesterol . 200 mg/dl). Forty-three patients
(83%) had a history of at least one prior CABG. The
mean ejection fraction (evaluated by MR imaging) was
51.4 6 12.0% (range 20% to 73%). Sixty-nine percent of
patients had NYHA class II or III symptoms of congestive
heart failure.
Acute results. The doses of rFGF-2 studied ranged from
0.33 mg/kg (based on ideal body weight) to 48 mg/kg and
are summarized in Table 2; the entire dose was administered
in each case. Two patients in the 48 mg/kg group had
hypotension. At 36 mg/kg, only one of 10 patients devel-
oped dose-limiting toxicity (leucocytosis and nausea delay-
ing discharge); this led to the designation of 36 mg/kg as the
MTD. Overall, there were no clinically significant
Table 1. Baseline Clinical Characteristics
All Patients (n 5 52)
Age 60.8 6 10.1
Men/women 50/2
Diabetes mellitus 6 (11%)
Hypertension 22 (42%)
Elevated cholesterol* 31 (60%)
Prior CABG 43 (83%)
Multiple prior CABG (2 or 3) 12 (23%)
Prior PTCA 26 (50%)
New York Heart Association class
Class 0 1 (2%)
Class I 11 (21%)
Class II 25 (48%)
Class III 11 (21%)
Class IV 4 (8%)
Ejection fraction by MR analysis (%) 51.4 6 12.0 (range 20–73)
*Serum cholesterol . 200 mg/dl.
CABG 5 coronary artery bypass grafting; EF 5 ejection fraction; PTCA 5
percutaneous transluminal coronary angioplasty, MR 5 magnetic resonance imaging
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hemodynamic effects even at the highest doses. The mean
arterial pressure was 96.0 6 10.5 mm Hg at baseline,
90.0 6 13.1 mm Hg during the infusion, and 86.3 6
9.6 mm Hg at 7 h.
Clinical follow-up and safety assessment. Clinical
follow-up of at least six months was obtained on all patients.
A total of 30 serious adverse events were reported in 22
patients (Table 2). There was no apparent relationship
between increasing dose of rFGF-2 and serious adverse
events.
Four patients died. Two deaths were sudden and occurred
22 days (0.65 mg/kg dose, EF 30%) and 114 days (48 mg/kg
dose, EF 22%) after rFGF-2 infusion. One patient
(2 mg/kg) died 72 days after rFGF-2 infusion from com-
plications of cardiac transplantation after sustaining several
myocardial infarctions beginning four days after drug infu-
sion. One patient with preexisting lymphadenopathy
(6 mg/kg) died at 62 days from septic complications of
large-cell lymphoma, which was diagnosed at 10 days after
dosing. In retrospect, the lymphoma most likely predated
rFGF-2 infusion. One additional patient was diagnosed
with metastatic adenocarcinoma to the liver at day 431.
Four patients had non-Q-wave myocardial infarctions at
days 5 (2 mg/kg dose group), 68 (6 mg/kg), 132 (0.33 mg/kg)
and 146 (48 mg/kg). Four patients had revascularization
procedures (CABG and aortic valve replacement in one
patient at day 68 [6 mg/kg] and PTCA in three patients at
day 100 [0.33 mg/kg], 290 [24 mg/kg], and 223 [48 mg/kg]).
One patient developed atrial fibrillation at day 37. The most
commonly reported (.10% of patients) adverse events were
asthenia (19%), chest pain (19%), hypotension (15%), dys-
pnea (13%), insomnia (13%), angina (12%) and palpitations
(12%). Of these asthenia, hypotension, insomnia, and dys-
pnea were more common at higher doses. No patients
withdrew from the study because of adverse events. Tran-
sient leukocytosis was observed in half the patients at
$24 mg/kg. Fluctuations in renal function occurred but
were transient and not dose related. Proteinuria (.250
mg/24 h) occurred in four patients (7.8%). Ophthalmolog-
ical exams with fundus photography at baseline and day 57
were available for 45 patients; seven patients lacked either
baseline or 57-day assessments. Forty patients (89%)
showed no change from baseline, two patients improved by
two ETDRS grades and three patients worsened by two
grades (0.65, 2.0 and 36.0 mg/kg groups).
The presence of anti-rFGF-2 antibodies was assessed at
baseline and days 15, 57 and 180. There were no clinically
significant changes in antibody titers.
Quality of life assessment. There were significant im-
provements in all five scales of the Seattle Angina Ques-
tionnaire at days 57 and 180, as compared with baseline
(Fig. 1). In particular, angina frequency score increased
(denoting improvement) from 39.8 6 3.8 at baseline to
68.8 6 4.0 (p , 0.001) at day 57 and 64.7 6 4.5 at day 180
(p , 0.001), overall p , 0.001. Exertional capacity score
Figure 1. Quality of life assessment using the Seattle Angina Question-
naire showed significant improvements in all five scales (angina frequency,
angina stability, exertional capacity, disease perception, and treatment
satisfaction) at days 57 (gray bar) and 180 (checkered bar) as compared to
baseline (black bar). Data presented as mean 6 SEM. *Denotes statistical
significance, p , 0.05.
Figure 2. Exercise treadmill times in patients with matched baseline and
follow-up protocols showed minimal improvement at day 29 with more
significant improvement at day 57 and day 180. Data presented as mean 6
SEM. *Denotes p 5 0.023 (for day 29), **denotes p , 0.001 for days 57
and 180.
Table 2. Serious Adverse Events at Different Dose Levels
Dose Group
mg/kg*
Patients
Dosed
(n)
Related
Events
(n)
Unrelated
Events
(n)
Total
Events
(patients)
0.33 4 6 2 8 (3)
0.65 4 1 2 3 (2)
2 8 1 4 5 (3)
6 4 1 2 3 (3)
12 4 0 2 2 (2)
24 8 1 1 3 (3)
36 10† 2 1 3 (3)
48 10† 2 1 3 (3)
Total 52 14 15 30 (22)
*Ideal body weight. †Two patients in 48 mg/kg group (#4 and #10) experienced
dose-limiting toxicities (one patient had hypotension lasting .10 minutes and one
patient had orthostatic hypotension which delayed discharge). Only 1 of 10 patients
at 36 mg/kg had significant toxicity (leukocytosis and nausea delaying discharge).
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increased from 49.2 6 2.8 at baseline to 64.5 6 3.1 at day
57 (p , 0.001) and 73.0 6 3.8 at day 180 (p , 0.001),
overall p , 0.001.
Exercise treadmill testing. A subset of patients with
matching baseline and follow-up exercise treadmill proto-
cols was selected for analysis (Fig. 2). Among this group, the
mean exercise time improved from 510 6 24 s at baseline
(n 5 35) to 561 6 26 s at day 29 (n 5 28; p 5 0.023),
609 6 26 s at day 57 (n 5 31; p , 0.001), and 633 6 24 s
at day 180 (n 5 23; p , 0.001).
Left ventricular function assessment. Magnetic reso-
nance imaging was performed in 51 patients at baseline and
was repeated at days 29 (n 5 47), 57 (n 5 45) and 180 (n 5
31) to assess resting left ventricular ejection fraction, re-
gional wall motion, and myocardial contrast arrival. There
was a small improvement in overall left ventricular ejection
fraction over the course of the study (baseline 51.4 6 1.7%,
day 29: 54.2 6 1.7% [p 5 0.02], day 57: 55.2 6 1.9% [p 5
0.003], day 180: 57.2 6 1.7% [p , 0.001], overall p 5
0.002). The hypoperfused target area was selected for
resting regional left ventricular wall motion analysis. Sys-
tolic thickening of this area (target wall) and normal wall
were measured using a semiautomated quantification algo-
rithm of short-axis MR images. Resting normal wall systolic
thickening was 46.1 6 1.6% at baseline and did not change
significantly throughout the study duration (p 5 0.16).
Resting target wall thickening was significantly lower than
normal wall thickening at baseline (34.0 6 1.7% vs. 46.1 6
1.6%, p , 0.001). Target wall thickening significantly
improved at days 29, 57, and 180 as compared to baseline
[baseline: 34 6 1.7%, day 29: 38.7 6 1.9% (p 5 0.006), day
57: 41.4 6 1.9% (p , 0.001), and day 180: 42.0 6 2.3%
(p , 0.001), overall p 5 0.001] (Fig. 3).
Myocardial perfusion assessment. Myocardial perfusion
was assessed using MR imaging (Fig. 4). The mean size of
the delayed contrast arrival zone was 15.4 6 0.8% of the left
ventricle at baseline and was similar to the global left
ventricular extent of ischemia determined by nuclear perfu-
sion imaging (17.3 6 1.8%). The size of the myocardial area
demonstrating delayed contrast arrival was significantly
reduced from baseline (15.4 6 0.8%) at day 29 (9.0 6 0.6%,
p , 0.001), day 57 (5.6 6 0.7%, p , 0.001) and day 180
(4.9 6 0.8%, p , 0.001), overall p , 0.001.
There was no correlation between the dose used and the
various efficacy parameters studied.
DISCUSSION
In this Phase I trial, safety, tolerability and preliminary
efficacy of a single intracoronary infusion of rFGF-2 were
evaluated in patients with advanced coronary disease who
could not be optimally managed using conventional medical
therapy or standard revascularization procedures. In this
population, rFGF-2 administered as an IC infusion was
well tolerated over a 100-fold dose range (0.33 mg/kg to
36 mg/kg). Hypotension was dose-related and dose limiting;
in all cases, it was manageable by administration of IV
fluids. The MTD was 36 mg/kg. Laboratory safety param-
eters and retinal examinations demonstrated mild and
mainly transient changes.
Serious adverse events were common but did not appear
to be dose related. Four deaths and four major cardiac events
occurred but did not appear to be related to dose or time of
administration. Preliminary efficacy data suggested im-
provement in the patients’ quality of life as assessed by SAQ
and in exercise tolerance measured by treadmill exercise
testing.
In addition to these relatively subjective endpoints in this
open-label study, there was objective evidence of increased
regional wall motion and improved myocardial perfusion in
Figure 3. Regional wall thickening was measured using magnetic reso-
nance imaging. Baseline (black bar) target wall thickening was significantly
reduced compared to normal wall thickening and improved at days 29
(white bar), 57 (gray bar) and 180 (checkered bar). Data presented as
mean 6 SEM. *Denotes statistical significance with p , 0.01.
Figure 4. Magnetic resonance perfusion imaging allowed the determina-
tion of the extent of the myocardial area with delayed contrast arrival,
which was significantly reduced at days 29 (white bar), 57 (gray bar) and
180 (checkered bar), as compared to baseline (black bar). Data presented
as mean 6 SEM. *Denotes statistical significance with p , 0.001.
2136 Laham et al. JACC Vol. 36, No. 7, 2000
Intracoronary FGF-2 in Coronary Artery Disease December 2000:2132–9
the most ischemic areas of the heart at all time points
compared with baseline.
SAFETY AND TOLERABILITY OF RFGF-2 ADMINISTRATION.
The ability to administer fairly high doses of rFGF-2 (up to
36 mg/kg IC) without significant hemodynamic effects is
somewhat surprising given prior reports of severe FGF-2-
induced hypotension (11) and the known capacity of this
cytokine to stimulate NO release and induce arteriolar
vasodilation (33). Hypotension was dose-related and dose
limiting, but was rapidly correctable by IV fluids. This
finding is in sharp contrast to clinical experience with
another NO-releasing growth factor, VEGF-A165, where
profound hypotension limits systemic administration (34).
This difference in part may be attributable to careful
hemodynamic monitoring in these patients and a require-
ment for adequate filling pressure (.12 mm Hg) before
initiation of rFGF-2 infusion.
Preclinical studies as well as limited clinical experience to
date suggested that renal insufficiency due to membranous
nephropathy accompanied by proteinuria (35) may be the
most significant long-term side effect of FGF-2 adminis-
tration. In this small trial, only four instances of proteinuria
were observed. It should be noted, however, that all patients
studied had normal renal function at baseline.
Four patients died during follow-up (8% mortality). Two
deaths were sudden, one death was due to complications of
cardiac transplantation and one death was due to compli-
cations of large-cell lymphoma. Both instances of sudden
death occurred in patients with reduced left ventricular
function (22% and 30%). Although sudden death may be
part of the natural history of their disease, potential partial
revascularization in these patients may have induced ven-
tricular tachyarrhythmias. The diagnosis of large-cell non-
Hodgkin’s lymphoma 10 days after rFGF-2 infusion most
likely reflected the presence of disease that antedated IC
rFGF-2 administration. Nevertheless, it is possible that
rFGF-2 may have exacerbated the lymphoma course (36).
Additional serious side effects included the occurrence of
non-Q-wave myocardial infarction in four patients, raising
the possibility that FGF-2 may have promoted growth, or
destabilization of coronary plaque (37,38) owing to its
broad-spectrum mitogenicity and chemotactic activity. The
latter possibility may be particularly relevant given the
ability of FGFs to induce angiogenesis in vasa vasorum
(37–39) and the association between plaque angiogenesis
and its growth (40,41) and stability (42). Although these
concerns are certainly worrisome, in the absence of a control
group causal relationships cannot be confirmed or dis-
counted.
PRELIMINARY EFFICACY OF RFGF-2 THERAPY. Although the
small sample size and the absence of a control group
preclude any definitive conclusions regarding efficacy, sev-
eral findings suggest potential clinical benefits of intracoro-
nary rFGF-2 administration. In particular, quality of life, as
assessed by the SAQ, improved in treated patients at day 57
compared with baseline, and this improvement was sus-
tained for six months. The magnitude of improvements in
the five SAQ scales was similar to that seen following
PTCA and CABG in patients with ischemic heart disease
(29,30). There was also a significant improvement in exer-
cise capacity, as measured by exercise treadmill testing, seen
at days 57 and 180. Of note, there was minimal improve-
ment at day 29. The late occurrence of improvement in
exercise testing is in keeping with the assumed time course
of coronary angiogenesis. However, the absence of a dose
response tempers the preliminary efficacy seen in this study.
In addition to these subjective measures of clinical status,
resting MR imaging was performed to assess left ventricular
function and myocardial perfusion. Using this approach we
detected no difference in overall left ventricular ejection
fraction at any time during the study. However, there was a
significant improvement in systolic thickening of the target
wall at day 29, which was maintained at six months, and was
paralleled by a significant reduction in the size of the
ischemic myocardium as assessed by blood arrival imaging.
Although cardiac MR imaging is considered the “gold
standard” for evaluation of left ventricular function (43,44),
its application to clinical trials in coronary disease is very
limited (45). Similarly, despite recent advances in MR-
based perfusion assessment of the myocardium (31,32,46),
there has been no substantial clinical experience with this
imaging modality (47). In prior animal studies we have
documented improvement in MR-assessed parameters of
left ventricular function in the setting of angiogenic growth
factor therapy (9,48). In addition, the newly developed
variation of MR perfusion imaging that relies on generation
of space-time maps proved capable of detecting changes in
coronary perfusion in a pig ameroid model (31) and proved
capable of detecting improved regional myocardial perfusion
in patients treated with epicardially administered sustained
release FGF-2 (49).
Clinical trials of coronary angiogenesis. It is important to
consider the result of this trial in light of other recently
reported trials of therapeutic coronary angiogenesis. The
phase I open-label study of intracoronary (n 5 15) and
intravenous (n 5 28) VEGF165 reported improvements in
both angina class and exercise performance. However, a
larger double-blind study of a single intracoronary infusion
of VEGF165 followed by three intravenous infusions over
seven days, failed to demonstrate any improvement in
symptoms, exercise testing or nuclear perfusion imaging at
day 60 compared with placebo controls (34). These results
underscore the unreliability of an open-label study design to
assess efficacy and an unusually large and long-lasting
placebo effect in this patient population. We have reported
a randomized, double-blind, placebo-controlled trial of
sustained release FGF-2 administered perivascularly in con-
junction with CABG that demonstrated improved myocar-
dial perfusion in territories treated with 100 mg FGF-2 but
not 10 mg FGF-2 or placebo (49).
A fundamental question pertaining to IC delivery is how
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a drug with a relatively short plasma half-life can promote a
relatively long-term process such as new collateral forma-
tion. One possible explanation is that first-pass extraction at
the desired site of action is the primary determinant of
FGF-2 biological effect. Although such extraction certainly
occurs, animal studies demonstrated that ,1% of 125I-
FGF-2 administered using the intracoronary route is de-
posited in the myocardium at 1 h and much less remains at
24 h (50). Although there is enhanced first-pass FGF-2
uptake in ischemic compared with normal myocardium
(50), presumably due to increased expression of cellular
heparan sulfates and FGF receptor-1 (51), myocardial levels
fall to very low levels at 24 h in both normal and ischemic
regions of the heart (50). One speculative explanation is that
this transient accumulation of FGF-2 in the ischemic
myocardium sets in motion a self-amplifying cascade that
includes the influx and endothelial adhesion of monocytes/
macrophages (52) and stimulation of expression of VEGF
and other angiogenic cytokines, which may lead to pro-
longed and sustained action (5).
Conclusions. This Phase I, open-label dose-escalation
study of a single IC infusion of rFGF-2 in patients with
severe ischemic heart disease supports the safety and toler-
ability of this mode of FGF-2 delivery. This was accompa-
nied by an improvement in quality of life, exercise capacity,
and regional left ventricular function, and a reduction in the
extent of resting myocardial ischemia as assessed by MR
imaging in this uncontrolled study. The efficacy and safety
of IC rFGF-2 is currently being evaluated in a large Phase
II, randomized, double-blind placebo-controlled trial
(FIRST, FGF-2 Initiating Revascularization Support
Trial).
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